Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.
Eur J Pharm Biopharm. 2012 Feb;80(2):453-8. doi: 10.1016/j.ejpb.2011.10.008. Epub 2011 Oct 18.
Photodynamic therapy (PDT) is a palliative therapy and has been used to cure cholangiocarcinoma (CC), which has a poor prognosis and limited available curative therapy. PDT was shown to improve the median survival time of advanced-stage patients. Recently, 5-aminolevulinic acid (ALA) has been used as a pro-photosensitizer, which can be transferred to intercellular protoporphyrin IX (PpIX), which is a strong photosensitizer, via the heme pathway. The main limitation of using ALA in PDT is the hydrophilic properties of ALA, which results in low cellular uptake. In this study, non-ionic surfactants, pluronic F68 (PF68) and Tween 80 (TW80), were used to address this limitation. The human CC cell line, HuCC-T1, was cotreated with ALA and different concentrations of surfactants for 4h. The effect of surfactants was evaluated by monitoring the uptake of ALA, the fluorescence intensity of PpIX, and the cell survival rate after suitable light irradiation. Cotreatment with the surfactant resulted in an increased intracellular ALA level, PpIX formation, and phototoxicity.
光动力疗法(PDT)是一种姑息疗法,已被用于治疗胆管癌(CC),该疾病预后较差,可选择的治疗方法有限。PDT 已被证明可以延长晚期患者的中位生存时间。最近,5-氨基酮戊酸(ALA)已被用作预敏剂,通过血红素途径可将其转化为细胞内原卟啉 IX(PpIX),这是一种强光敏剂。在 PDT 中使用 ALA 的主要限制是 ALA 的亲水性,这导致细胞摄取率低。在这项研究中,使用非离子表面活性剂泊洛沙姆 F68(PF68)和吐温 80(TW80)来解决这一限制。将人胆管癌细胞系 HuCC-T1 与 ALA 和不同浓度的表面活性剂共同孵育 4 小时。通过监测 ALA 的摄取、PpIX 的荧光强度以及适当光照后细胞存活率来评估表面活性剂的作用。表面活性剂的共同处理导致细胞内 ALA 水平、PpIX 形成和光毒性增加。